[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642079":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":63,"collaborators":25,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":25,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":25,"enrollmentInfo":75,"targetDuration":25,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":90,"whyStopped":25,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Conventional treatment without propranolol","EXPERIMENTAL","Patients are provided with conventional supportive treatment only, but without nonselective beta blockers.",[13],"Other: conventional therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Conventional treatment combined with propranolol","ACTIVE_COMPARATOR","Patients are administered with propranolol in addition to conventional treatment.",[19],"Drug: propranolol",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"conventional therapy","Conventional treatment of decompensated cirrhosis mainly includes anti-hepatic fibrosis drugs, albumin infusion, diuretics, peritoneal drainage, esophageal variceal ligation, endoscopic tissue adhesive injection, blood purification, and liver transplantation.",[9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","propranolol","Propranolol will be started with 10-20 mg\u002Fday for the propranolol group, which will be gradually increased to the maximum tolerance dosage or achieve a heart rate of 55-60 beats per minute and a systolic blood pressure of 90mmHg.",[15],[32],"Inderal",[34],{"name":35,"affiliation":36,"role":37},"Li He","Department of Gastroenterology, General Hospital of Northern Theater Command","PRINCIPAL_INVESTIGATOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":25,"email":43},"Xingshun Qi, MD","CONTACT","18909881019","xingshunqi@126.com",{"name":35,"role":41,"phone":45,"phoneExt":25,"email":46},"18473457053","lihee228@163.com",[48],{"facility":49,"status":25,"city":50,"state":51,"zip":25,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Department of Gastroenterology, General Hospital of Northern Theater Command (formerly called General Hospital of Shenyang Military Area)","Shenyang","Liaoning","China","CN",{"type":55,"coordinates":56},"Point",[57,58],123.43278,41.79222,{"lat":58,"lon":57},[61,62],{"name":40,"role":41,"phone":42,"phoneExt":25,"email":43},{"name":35,"role":41,"phone":45,"phoneExt":25,"email":46},{"type":37,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Xingshun Qi","Director of Department of Gastroenterology","100642079","impact-of-propranolol-on-the-prognosis-of-patients-with-decompensated-cirrhosis-and-meld-score--9-100642079",false,"NCT07652203","Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9","Impact of Propranolol on the Prognosis of Patients With Decompensated Cirrhosis and MELD Score > 9: a Non-inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n* patients' age ≥18 years;\n* patients with a definitive diagnosis of liver cirrhosis;\n* patients with a MELD score of \\>9;\n* patients with a history of decompensation or those who are experiencing their first decompensation, such as ascites, variceal bleeding, or hepatic encephalopathy (HE);\n* patients' informed consents.\n\nExclusion Criteria:\n\n* patients without a definite indication for NSBBs;\n* patients with an absolute contraindication of NSBBs (severe bronchospasm, asthma, severe psychosis, high-degree atrioventricular block, etc.);\n* patients with hypersensitivity to NSBBs;\n* patients who had been treated with NSBBs before 2 weeks of enrollment;\n* patients with occlusive portal vein thrombosis;\n* patients who had undergone liver transplantation;\n* patients who had undergone transjugular intrahepatic portosystemic shunt (TIPS);\n* patients with a definitive diagnosis of hepatocellular carcinoma;\n* patients with an estimated life time of \\\u003C12 months due to the presence of any comorbidities;\n* patients who are currently pregnant or breast-feeding.","ALL","18 Years",{"count":76,"type":77},466,"ESTIMATED","INTERVENTIONAL",[80],"NA","Non selective beta blockers (NSBBs), such as propranolol and nadolol, are mainstay therapies for portal hypertension in cirrhosis, but their efficacy and safety vary depending on the stage of the disease. Emerging evidence suggests that NSBBs may worsen the prognosis of advanced cirrhosis, especially in patients with a model for end-stage liver disease (MELD) score of \\>9. The purpose of this randomized controlled trial is to evaluate the effects of the use of propranolol as recommended by the guideline on the prognosis in cirrhotic patients with a MELD score of \\>9.",[83],"Cirrhosis",[85,28,86,87,88,89],"cirrhosis","decompensation","recompensation","survival","MELD","NOT_YET_RECRUITING","2026-06-11",{"date":93,"type":94},"2026-06-16","ACTUAL",{"date":96,"type":77},"2026-06",{"date":98,"type":77},"2028-07",{"name":5,"class":6},1]